Newsfeeds - Spark Newswire

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

Today, 9:47 AM

Gainers Enochian BioSciences (NASDAQ:ENOB) shares moved upwards by 27.8% to $2.3 during Wednesday's after-market session. The market value of their outstanding shares is at $121.7 million.

ATXI

2 minute read

Moleculin Receives FDA Orphan Drug Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme

By Benzinga Newsdesk

Today, 9:47 AM

- Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX)

MBRX

1 minute read

FDA
News

Moleculin Biotech Granted FDA Orphan Drug Designation For ‘an acetic acid diester of 2-deoxy-D-glucose’

By Benzinga Newsdesk

Today, 9:47 AM

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=896722

MBRX

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 9:47 AM

Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million.

ABVC

2 minute read

Recap Of Friday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 9:47 AM

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ:AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl)…

AXSM

1 minute read

Moleculin Biotech Doses Healthy Volunteers For Covid-19 In Early-Stage Study Of WP1122

By Ragothaman Srinivasan

Today, 9:47 AM

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced dosing of subjects in its Phase 1a clinical study of WP1122 in healthy volunteers for the treatment of COVID-19.

MBRX

3 minute read

Moleculin Biotech Reports Began Dosing In Volunteers For Phase 1a Trial Of Co.’s WP1122 For Treatment Of COVID

By Benzinga Newsdesk

Today, 9:47 AM

– Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose – – Multiple ascending dose (MAD) cohort to

MBRX

3 minute read

30 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 9:47 AM

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday.

AGRI

1 minute read

Moleculin Biotech Q1 EPS $(0.24) Down From $(0.20) YoY

By Benzinga Newsdesk

Today, 9:47 AM

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.24) per share. This is a 20 percent decrease over losses of $(0.20) per share from the same period last year.

MBRX

3 minute read

FDA
News

Moleculin Receives Allowance To Proceed With Phase 1/2 Study Of Annamycin In Combination With Cytarabine For The Treatment Of Acute Myeloid Leukemia

By Benzinga Newsdesk

Today, 9:47 AM

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and

MBRX